Emergent Biosolutions Inc
$ 8.32
-0.83%
12 Jun - close price
- Market Cap 429,281,000 USD
- Current Price $ 8.32
- High / Low $ 8.47 / 8.27
- Stock P/E N/A
- Book Value 10.10
- EPS -0.19
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE -0.02 %
- 52 Week High 14.06
- 52 Week Low 5.62
About
Emergent BioSolutions Inc., a life sciences company, focuses on providing preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHT). The company is headquartered in Gaithersburg, Maryland.
Analyst Target Price
$12.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-26 | 2025-10-29 | 2025-08-06 | 2025-05-07 | 2025-03-03 | 2024-11-06 | 2024-08-06 | 2024-05-01 | 2024-03-06 | 2023-11-07 | 2023-08-08 |
| Reported EPS | 0.21 | -0.43 | 1.06 | 0.16 | 0.71 | -0.5775 | 1.37 | -2.32 | 0.59 | -0.77 | -5.08 | -1.06 |
| Estimated EPS | -0.25 | 0.425 | -0.12 | -0.49 | 0.44 | -0.4957 | 0.14 | -0.97 | -0.83 | -0.19 | -0.54 | -0.62 |
| Surprise | 0.46 | -0.855 | 1.18 | 0.65 | 0.27 | -0.0818 | 1.23 | -1.35 | 1.42 | -0.58 | -4.54 | -0.44 |
| Surprise Percentage | 184% | -201.1765% | 983.3333% | 132.6531% | 61.3636% | -16.5019% | 878.5714% | -139.1753% | 171.0843% | -305.2632% | -840.7407% | -70.9677% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.855 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EBS
2026-06-11 15:39:37
Emergent BioSolutions Inc.'s SVP of Products Business, Paul Anthony Williams, had 694 shares of common stock withheld at $8.00 per share to cover tax obligations upon the vesting of restricted stock units. This transaction was a routine tax-related disposition, not an open-market sale. Following this, Williams directly holds 162,098 shares of EBS common stock.
2026-06-11 15:39:36
This article reports a Statement of Changes in Beneficial Ownership of Securities (Form 4) filed by Emergent BioSolutions. The filing pertains to Officer Williams Paul Anthony, indicating changes in his beneficial ownership of securities in the company.
2026-06-10 20:39:25
This document is a statement of changes in beneficial ownership of securities for Richard S. Lindahl, an officer at Emergent BioSolutions. It falls under SEC Form 4, which is used to report changes in ownership of company stock by insiders.
2026-06-10 19:39:25
Emergent BioSolutions Inc.'s EVP and CFO, Richard S. Lindahl, reported a routine tax-related disposition of 3,964 common stock shares at $8.00 each. These shares were withheld to cover taxes associated with the vesting of restricted stock units, not sold on the open market. Lindahl retains a substantial equity position in the company, holding 374,083 shares after the transaction.
2026-06-05 00:38:59
Emergent BioSolutions is partnering with Victoria’s Voice Foundation for National Naloxone Awareness Day to combat the opioid epidemic. The initiative focuses on increasing awareness and access to NARCAN® Nasal Spray through campaigns like "Shine. Wear. Share. Care." and the "Ready to Rescue" program. Both organizations emphasize the critical role of naloxone education and availability in saving lives and addressing the ongoing crisis.
2026-06-04 12:39:43
Emergent BioSolutions is partnering with Victoria’s Voice Foundation to support National Naloxone Awareness Day, aiming to combat the opioid epidemic by increasing awareness and access to NARCAN® Nasal Spray. The collaboration includes continuing the "Shine. Wear. Share. Care." campaign, distributing educational materials, and involving spokesperson Zac Clark to reach college communities. This initiative underscores the critical role of naloxone in overdose reversal and aligns with national efforts to expand access to life-saving tools.
